Institut Bergonié
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1923-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.bergonie.org
T-DXd-Pembrolizumab Combination Shows Promise in HER2-Positive NSCLC with 80% Response Rate in First-Line Setting
A phase 1b study reveals that combining trastuzumab deruxtecan (T-DXd) with pembrolizumab demonstrates significant antitumor activity in HER2-expressing and HER2-mutant non-small cell lung cancer. The combination achieved particularly impressive results in previously untreated patients, with response rates of 62.5% and 80% in HER2-expressing and HER2-mutant NSCLC respectively.
© Copyright 2025. All Rights Reserved by MedPath